The current standard‐of‐care treatment for DKD include the use of angiotensin‐converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and potentially sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors that primarily regulate hemodynamics and hyperglycemia (Brenner et al., 2001; Duckworth et al., 2009; Heerspink et al., 2020; Lewis et al., 2001; Muskiet et al., 2019; Perkovic et al., 2019; Sen & Heerspink, 2021; Wanner et al., 2016). Here, ACE is linked to diabetic kidney disease.